UPDATE: Oct. 30, 2020: Teladoc has completed its $18.5 billion acquisition of Livongo following overwhelming shareholder approval, the virtual care giant announced Friday.
Under the terms of the merger, Livongo shareholders will receive 0.5920…
Source: www.healthcaredive.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
